Loading...
Projects / Programmes source: ARIS

Modulacija imunskega odziva pri bolnikih z malignim melanomom rezistentnim na kemoterapijo (Slovene)

Research activity

Code Science Field Subfield
3.04.00  Medical sciences  Oncology   

Code Science Field
B200  Biomedical sciences  Cytology, oncology, cancerology 
Keywords
melanoma, lymphocytes T, allogeneic mononuclear cells, dendritic cells
Evaluation (rules)
source: COBISS
Researchers (13)
no. Code Name and surname Research area Role Period No. of publicationsNo. of publications
1.  17171  MSc Milan Baškovič  Oncology  Researcher  2000 - 2001  28 
2.  14932  MSc Zvezdana Hlebanja  Oncology  Researcher  1999 - 2001  74 
3.  04891  Breda Jančar  Oncology  Researcher  1999 - 2001  36 
4.  12022  PhD Barbara Jezeršek Novaković  Oncology  Researcher  1999 - 2001  332 
5.  08801  MSc Maksimiljan Kadivec  Oncology  Researcher  1999 - 2001  131 
6.  03171  PhD Aleksandra Markovič-Predan  Medical sciences  Researcher  2000 - 2001  284 
7.  13541  PhD Janja Ocvirk  Oncology  Researcher  1999 - 2001  827 
8.  04401  PhD Ana Pogačnik  Oncology  Researcher  1999 - 2001  168 
9.  08297  MSc Tanja Roš-Opaškar  Oncology  Researcher  1999 - 2001  42 
10.  08750  PhD Zvonimir Rudolf  Oncology  Researcher  1999 - 2001  258 
11.  04404  Marjeta Stanovnik  Oncology  Researcher  2000 - 2001  63 
12.  11949  PhD Borut Štabuc  Oncology  Head  1999 - 2001  677 
13.  07195  PhD Ivan Vrhovec  Oncology  Researcher  2000 - 2001  116 
Organisations (1)
no. Code Research organisation City Registration number No. of publicationsNo. of publications
1.  0302  Institute of Oncology Ljubljana  Ljubljana  5055733000  15,468 
Abstract
In a group of metastatic melanoma patients, resistent to irradiation, chemoterapy and treatment with immunomodulatory agents, the supressed immune response to tumors will be removed and eventual tumor regression as well as the effect on patients’ survival will be evaluated after stimulation the immune sistem. For that purpose cyclophosphamid, anti-lymphocyte T polyclonal and monoclonal antibodies will be applied leading to depletion of lymphocytes T, aiming mostly at activated supressor cells. This treatment will be followed by infusion of allogenic mononuclear cells to additionally remove supressive barriers and to non-specifically activate patient’s immune system. The concept of this approach is similar to desirable induction of graft versus leukemia effect (GvL) in bone-marrow transplantation. Specific anti-tumor cellular and humoral responses induced by deblocking the immune system will be amplified by the use of patient’s autologous dendritic cells, prepared in vitro from his peripheral blood mononuclear cells (monocytes), harvested prior to all treatments.
Views history
Favourite